Arkolith/Insider Trading/XFOR/Form 4

DiBiase Mary

Chief Operating OfficerX4 Pharmaceuticals, Inc (XFOR) · full profile →Form 4 · filed Jan 27, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$10K
Net Open-Market Flow
-$10K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 24, 2025Sell(S)22K$0.45$10K491K
Jan 23, 2025Grant(A)61K—$0513K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-002706) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML